Mechanisms of Chemically-Induced Toxicity for Medicinal Chemistry
ACS ProSpectives Conference
| Type |
Conference |
| Language |
English |
| Date |
May 18, 2008
to
May 20, 2008
|
| Venue |
The Sheraton Society Hill| Philadelphia, PA
Philadelphia,
PA
US
|
| Chemistry Specialties |
- medicinal and pharmaceutical chemistry
- medicine
|
| Chemistry Techniques |
|
| Contact |
ACS Perspectives
,
US
acsprospectives@acs.org
|
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
Conference chairs F. Peter Guengerich, Professor of Biochemistry and the Director of Vanderbilt’s Center in Molecular Toxicology, and Dr. James MacDonald, EVP of Preclinical Development at the Schering-Plough Research Institute, have developed this program to cover the chemical basis of toxicity as it applies to medicinal chemistry. Sessions will be held on reactive metabolites and alternative mechanisms, with an emphasis on specific chemical groups and methods of screening. Numerous case studies will be given throughout the program by scientists from Pfizer, Schering Plough, and Merck, among others.
The conference will also cover some newer methods and even future approaches to assessing the toxicity potential of compounds in humans, including “omics” approaches, and will provide a view of the current regulatory environment -- and therefore the level of likely acceptance of those methods.
Session titles
Gerald Miwa, formerly of Millennium, Keynote
Reactive Metabolite-Mediated Toxicity:
Kaushik Mitra, Department of Drug Metabolism and Pharmacokinetics, Merck on “Minimizing Metabolic Activation during Pharmaceutical Lead Optimization: Progress, Gaps and Future Directions”
Amit Kalgutakar of Pfizer on “Chemical Toxicophores and Their Potential for Trouble”
Mike Freeman, Prof. Radiation Oncology, Radiology, Cancer Biology at Vanderbilt University School of Medicine on “Coupling LC/MS/MS analysis with biochemical and cell biology-based approaches to identify reactive Keap1 cysteine residues that are critical for function: Insights into mechanisms regulating induction of Phase II metabolism”
Daniel C. Liebler, Director of the Jim Ayers Institute for Precancer Detection and Diagnosis and Professor of Biochemistry, Pharmacology and Biomedical Informatics at Vanderbilt University School of Medicine on “Covalent adduction of kinase sensors and induction of apoptosis”
Alternative Mechanisms of Chemical Toxicity:
Jim Klaunig of Indiana University on “Non-Genoxic Mechanisms of Carcinogenicity”
Ellen Evans of Schering-Plough on “Immune-mediated Tox, including a case study of Tegenero”
Alan Bass of Schering Plough Research Institute on “Non-reactive metabolite mediated tox focusing on cardiotoxicity”
Human Risk Assessment of Chemically-Mediated Toxicity:
Tom Begley of SUNY Albany on “Systems Biology and Functional Genomics Approaches for the Identification of Cellular Responses to Toxicants”
Bill Schaefer of Merck on “Proteomics and Metabolomics in Safety Assessment”
Rusty Thomas of the Hamner Institute/CIIT on “The Application of Transcriptomic Technology for Evaluating the Tumorigenic Potential of Chemicals”
Future Approaches to Assessment of Toxic Potential:
Jon Cook of Pfizer on PPAR-receptor agonist mediated tox
John Bucher of the NIEHS/NIH on the NTP Vision for the 21st Century
David Jacobson-Kram of the Office of New Drugs/Center for Drug Evaluation and Research at the FDA on where the field is going and the relative value of some of the newer technologies
Jiri Aubrecht of Pfizer on the future of tox testing
Cost
ACS Member: $1,395
Non-member: $1,595
More information about this event…